Myasthenia Gravis Treatment: FcRn Antagonists, Complement Inhibition, and Thymectomy in the Biologic Era
An evidence synthesis on modern myasthenia gravis treatment, covering efgartigimod, rozanolixizumab, and zilucoplan, with long-term MGTX thymectomy outcomes and the emerging role of immunosuppressant deprescribing.
One-Minute Takeaway on Myasthenia Gravis Treatment
One-Minute Takeaway
- Modern myasthenia gravis treatment now spans three pivotal mechanism classes: FcRn antagonists (efgartigimod, rozanolixizumab), terminal complement inhibitors (zilucoplan, eculizumab, ravulizumab), and surgical thymectomy.
- Across pivotal trials these biologics produce concordant improvements on the four core MG outcomes — MG-ADL, QMG, MGC, and MG-QoL15r — with effect sizes consistently exceeding the predefined minimal clinically important differences.
- The MGTX 5-year extension confirmed that thymectomy plus prednisone produces durable QMG benefit and prednisone-sparing effects in non-thymomatous AChR-positive generalised disease.
- Long-term open-label extension data and real-world cohorts support a shift toward immunosuppressant deprescribing strategies once biologic disease control is achieved.
- Comparative effectiveness data across these agents are absent; modality selection rests on antibody serotype, infection risk, route of administration, and access considerations.
Why Myasthenia Gravis Treatment Matters Now
Generalised myasthenia gravis affects approximately 14 to 20 per 100,000 people, with rising prevalence driven by improved diagnosis and longer survival. Although immunosuppression and thymectomy have been the mainstays for decades, up to 15% of patients have remained refractory to conventional therapy, with persistent disability and frequent crises.
Three regulatory approvals between 2021 and 2023 reset the therapeutic landscape. Efgartigimod, rozanolixizumab, and zilucoplan introduced targeted, rapidly acting mechanisms with favourable steroid-sparing potential. The accumulating five-year MGTX data have simultaneously refined the role of thymectomy and clarified its long-term benefit.
For the practicing neurologist, modern myasthenia gravis treatment is no longer reducible to a stepwise escalation from pyridostigmine through prednisone to non-steroidal immunosuppressants. The decision today involves matching antibody serotype to mechanism, weighing infection risk against steroid burden, and integrating MGTX-supported surgical pathways into long-term planning.
What Evidence Was Reviewed
This synthesis draws on eight pivotal randomised trials and a long-term extension study published between 2016 and 2023. Studies were selected for direct relevance to modern myasthenia gravis treatment decisions across antibody serotypes (AChR-positive, MuSK-positive) and disease severity. Sample sizes range from 86 to 200 participants, reflecting the size of contemporary phase 3 programmes in this rare disease.
| Study | Design | n | Comparison | Key Finding |
|---|---|---|---|---|
| ADAPT (Howard 2021) | Phase 3 RCT | 167 | Efgartigimod IV vs placebo | MG-ADL responders 67.7% vs 29.7% (AChR+) |
| MycarinG (Bril 2023) | Phase 3 RCT | 200 | Rozanolixizumab vs placebo | MG-ADL Δ −3.4 vs −0.8 |
| RAISE (Howard 2023) | Phase 3 RCT | 174 | Zilucoplan vs placebo | MG-ADL Δ −4.39 vs −2.30 |
| REGAIN (Howard 2017) | Phase 3 RCT | 125 | Eculizumab vs placebo | MG-ADL improved on sensitivity analyses |
| CHAMPION-MG (Vu 2022) | Phase 3 RCT | 175 | Ravulizumab vs placebo | MG-ADL Δ −3.1 vs −1.4 |
| MGTX (Wolfe 2016) | RCT — thymectomy | 126 | Thymectomy + prednisone vs prednisone | 3-yr time-weighted QMG 6.15 vs 8.99 |
| MGTX extension (Wolfe 2019) | 5-year follow-up | 111 | Long-term thymectomy outcomes | Sustained QMG and prednisone-sparing benefit |
| Sanders IVIG/PLEX (Neurology 2014) | Comparative RCT | 84 | IVIG vs PLEX (worsening) | Comparable QMG response at day 14 |
Key Findings on Myasthenia Gravis Treatment
The contemporary evidence base for myasthenia gravis treatment is anchored on four standardised outcomes that recur across all major trials: the MG-Activities of Daily Living scale, the Quantitative Myasthenia Gravis score, the MG Composite, and the MG-QoL15-revised quality-of-life instrument. The four findings below synthesise pivotal trial results across these outcome domains.
Theme 1: FcRn Antagonism — Effects Across MG-ADL, QMG, MGC, and MG-QoL
The ADAPT phase 3 trial randomised 167 adults with generalised myasthenia gravis to four weekly infusions of efgartigimod 10 mg/kg or placebo. Among AChR-antibody-positive patients, 67.7% of efgartigimod-treated participants were MG-ADL responders versus 29.7% on placebo. Improvements were concordant on QMG, MGC, and MG-QoL15r, satisfying minimal clinically important difference thresholds across all four outcomes.
MycarinG extended the FcRn class to subcutaneous rozanolixizumab in 200 patients including both AChR-positive and MuSK-positive serotypes. Mean MG-ADL change at day 43 was −3.4 with rozanolixizumab versus −0.8 with placebo. The convergent efficacy across two FcRn antagonists with different antibody serotype coverage establishes IgG depletion as a foundational mechanism in modern myasthenia gravis treatment.
Theme 2: Terminal Complement Inhibition — Zilucoplan, Eculizumab, and Ravulizumab
RAISE randomised 174 adults with AChR-positive generalised disease to daily subcutaneous zilucoplan 0.3 mg/kg or placebo. The mean change in MG-ADL at week 12 was −4.39 with zilucoplan versus −2.30 with placebo, with a between-group difference of −2.09 (95% CI −3.24 to −0.95). Concordant effects were seen on QMG and MGC.
REGAIN and CHAMPION-MG provide complementary evidence. Eculizumab in REGAIN improved MG-ADL on prespecified sensitivity analyses despite missing the worst-rank ANCOVA primary outcome. Ravulizumab in CHAMPION-MG produced an MG-ADL change of −3.1 versus −1.4 placebo at week 26. The class signal supports terminal complement inhibition as a mechanistically distinct option, particularly for AChR-positive myasthenia gravis treatment with refractory generalised disease.
Theme 3: MGTX Thymectomy — Long-Term Confirmation Across the Same Outcomes
MGTX randomised 126 adults with non-thymomatous AChR-positive generalised disease to extended transsternal thymectomy plus prednisone or prednisone alone. At three years, time-weighted average QMG was 6.15 in the thymectomy arm versus 8.99 in the medical arm — a difference of −2.85 (95% CI −4.61 to −1.10). Average prednisone dose was 44 mg versus 60 mg per day.
The five-year extension followed 111 of the original participants. Both QMG and prednisone-sparing benefits were sustained at five years, with thymectomy patients also showing fewer hospitalisations for symptom exacerbations. These findings position thymectomy as the only intervention in modern myasthenia gravis treatment with randomised evidence of durable five-year disease modification across the four standardised outcomes.
Theme 4: Immunosuppressant Deprescribing in the Biologic Era
Long-term open-label extension data from ADAPT, MycarinG, and RAISE consistently report concomitant reduction in corticosteroid and non-steroidal immunosuppressant doses once disease control is achieved with biologic therapy. Real-world cohorts reproduce this pattern, with median prednisone reductions of 30 to 50% reported in registry follow-up.
No randomised trial has yet directly tested a biologic-anchored steroid-tapering protocol versus continued combination immunosuppression. The available evidence is therefore observational and supportive rather than definitive. Nonetheless, the evidence base across all four MG outcomes increasingly supports a deprescribing-oriented approach when biologic therapy delivers sustained disease control in modern myasthenia gravis treatment.
The four pivotal MG outcomes — MG-ADL, QMG, MGC, and MG-QoL15r — now move concordantly under FcRn antagonism, complement inhibition, and thymectomy, providing the evidence backbone for modern myasthenia gravis treatment.
— Synthesis of ADAPT, MycarinG, RAISE, REGAIN, CHAMPION-MG, and MGTX evidence
Quality & Consistency of Evidence
The evidence base for modern myasthenia gravis treatment rests on adequately powered phase 3 randomised trials with standardised outcome measures and pre-registered protocols. Long-term extension data and a single landmark surgical trial extend beyond short-term efficacy. Comparative effectiveness data and head-to-head trials are the principal evidence gaps.
- FcRn antagonist efficacy: concordant across ADAPT and MycarinG with consistent direction across all four standardised outcomes; tier 1 certainty for AChR-positive disease.
- Thymectomy long-term benefit: MGTX initial trial and 5-year extension are concordant; among the highest-quality surgical evidence in any neuromuscular condition.
- Complement inhibitor class effect: RAISE, REGAIN, and CHAMPION-MG show convergent benefit in AChR-positive disease, with REGAIN’s primary endpoint result complicating direct comparison.
- Steroid-sparing effects: consistent across long-term extension studies and real-world cohorts but not yet established by dedicated randomised tapering trials.
- Comparative effectiveness across mechanisms: evidence is limited — no head-to-head trials of FcRn antagonists versus complement inhibitors have been completed, leaving choice driven by indirect comparison.
What the Evidence Does Not Show
Despite a productive trial pipeline, several questions central to practical myasthenia gravis treatment remain unanswered. Each gap below identifies a specific evidence limitation rather than a generic call for more research.
⚠ Specific Knowledge Gaps
- No head-to-head randomised trial has compared FcRn antagonists with terminal complement inhibitors on the four standardised MG outcomes.
- Optimal sequencing of biologic therapy with thymectomy in patients eligible for both — including timing of surgery in patients already on FcRn antagonism — lacks prospective trial guidance.
- Dedicated randomised steroid-tapering protocols anchored on biologic disease control have not been performed; current deprescribing evidence is observational.
- Efficacy and safety of these biologics in seronegative generalised myasthenia gravis treatment remain incompletely characterised; pivotal trials primarily enrolled AChR-positive populations with smaller MuSK-positive subgroups.
- Long-term safety beyond two to three years for efgartigimod, rozanolixizumab, and zilucoplan — including infection risk, hypoalbuminaemia patterns, and meningococcal risk — depends on registry data accumulating over time.
- Cost-effectiveness of biologic-first myasthenia gravis treatment versus traditional immunosuppression has not been established by formal health-economic randomised analyses.
Practical Implications for Myasthenia Gravis Treatment
Based on the current evidence, the following considerations support clinical decision-making in myasthenia gravis treatment. Each implication reflects what the trial data support rather than a directive recommendation.
Evidence Supports Antibody-Serotype-Guided Selection
ADAPT, MycarinG, and RAISE data support choosing biologic class by antibody serotype: rozanolixizumab covers both AChR and MuSK serotypes; complement inhibitors are restricted to AChR-positive disease.
FcRn Antagonism Shows Suitability for Cyclic Disease Control
ADAPT’s cyclic dosing design supports efgartigimod for patients whose disease pattern fits intermittent IgG depletion, rather than continuous suppression.
MGTX Evidence Supports Thymectomy in Eligible Adults
MGTX initial and extension data support transsternal thymectomy for non-thymomatous AChR-positive generalised disease, with sustained 5-year benefit on QMG and prednisone exposure.
Deprescribing Evidence Supports Biologic-Anchored Tapering
Long-term extension and registry data support a structured corticosteroid taper once biologic disease control is established, with monitoring on MG-ADL and QMG.
Patient preference, infection risk, route of administration, vaccination history, and access infrastructure should anchor any individual myasthenia gravis treatment plan. Trial evidence describes population-level effects; the consultation translates them into a strategy for one person.
Evidence Grade & Bottom Line
Overall Evidence Grade: Strong for FcRn antagonists and thymectomy; Moderate for complement inhibitor class; Limited for deprescribing strategies. Multiple adequately powered randomised trials with concordant findings across the four standardised MG outcomes support the modern biologic and surgical pillars. Steroid-sparing observations are consistent but not yet supported by dedicated randomised tapering trials.
Bottom Line
- Modern myasthenia gravis treatment now offers three distinct biologic mechanisms with concordant pivotal trial benefit on MG-ADL, QMG, MGC, and MG-QoL15r.
- FcRn antagonists efgartigimod and rozanolixizumab provide rapid IgG depletion with broad serotype coverage when rozanolixizumab is selected.
- Terminal complement inhibitors zilucoplan, eculizumab, and ravulizumab provide an alternative mechanism for AChR-positive disease with refractory features.
- The MGTX five-year extension confirms thymectomy’s durable benefit in non-thymomatous AChR-positive generalised disease, supporting its continued role alongside biologic therapy.
- Immunosuppressant deprescribing is a reasonable goal when biologic disease control is established but requires structured monitoring and is not yet supported by dedicated randomised tapering trials.
Article Information & References
Disclaimer
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.
References
- Howard JF Jr, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526-536. DOI: 10.1016/S1474-4422(21)00159-9
- Bril V, Drużdż A, Grosskreutz J, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023;22(5):383-394. DOI: 10.1016/S1474-4422(23)00077-7
- Howard JF Jr, Bresch S, Genge A, et al. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol. 2023;22(5):395-406. DOI: 10.1016/S1474-4422(23)00080-7
- Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976-986. DOI: 10.1016/S1474-4422(17)30369-1
- Vu T, Meisel A, Mantegazza R, et al. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. NEJM Evid. 2022;1(5):EVIDoa2100066. DOI: 10.1056/EVIDoa2100066
- Wolfe GI, Kaminski HJ, Aban IB, et al. Randomized Trial of Thymectomy in Myasthenia Gravis. N Engl J Med. 2016;375(6):511-522. DOI: 10.1056/NEJMoa1602489
- Wolfe GI, Kaminski HJ, Aban IB, et al. Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurol. 2019;18(3):259-268. DOI: 10.1016/S1474-4422(18)30392-2
- Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011;76(23):2017-2023. DOI: 10.1212/WNL.0b013e31821e5505
- Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology. 2016;87(4):419-425. DOI: 10.1212/WNL.0000000000002790
- Narayanaswami P, Sanders DB, Wolfe G, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology. 2021;96(3):114-122. DOI: 10.1212/WNL.0000000000011124
- Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol. 2010;10:46. DOI: 10.1186/1471-2377-10-46
- Howard JF Jr, Bril V, Burns TM, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019;92(23):e2661-e2673. DOI: 10.1212/WNL.0000000000007600